A clinical trial is currently being conducted to evaluate the safety and immunogenicity of vaccines designed to protect against the avian influenza A/H5 virus. The study, which is taking place at Rochester Clinical Research, seeks to determine the effectiveness of different dose levels of egg-derived vaccines in stimulating an immune response in healthy individuals.
Study Design and Objectives
The trial involves administering two injections of the investigational vaccine, separated by a period of approximately 21 days. The primary objective is to assess the safety profile of the vaccine and to measure the magnitude and duration of the immune response generated in participants. This includes evaluating antibody titers and other markers of immune activation following vaccination.
Inclusion Criteria and Participant Demographics
Eligible participants include healthy adults aged between 18 and 64 years, as well as individuals aged 65 and older. To ensure a homogenous study population, participants are required to have a body mass index (BMI) of less than 35 kg/m2. Exclusion criteria may apply based on other health conditions, as determined by the study investigators.
Public Health Significance
Avian influenza viruses, such as A/H5, pose a significant threat to public health due to their potential to cause severe illness in humans. Transmission typically occurs through direct contact with infected birds or contaminated environments. Symptoms in humans can range from mild respiratory issues to severe pneumonia and other life-threatening complications. Preventive measures, including vaccination, are crucial for controlling the spread of the virus and protecting vulnerable populations.
Study-Related Care and Compensation
Participants enrolled in the clinical trial will receive study-related medical care at no cost. Health insurance is not a requirement for participation. Further details regarding compensation for time and travel may be available from the study organizers.
